Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）
Status:
Active, not recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, prospective, randomized, open-Label, single-center international study
that assesses the efficacy and safety of neoadjuvant therapy with different cycles of
sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the
biomarkers of neoadjuvant immunochemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University